Discover
ELVN
Enliven Therapeutics, Inc.
58.49
1 x 58.45
1 x 58.55
bid
ask
-
0.93
1.57%
01:30 PM
timesize
| Ytd | 279.81% | |
| 1y | 222.97% |
57.46
day range
59.24
14.79
52 week range
62.32
| Open | 58.90 | Prev Close | 59.42 | Low | 57.46 | High | 59.24 | Mkt Cap | 4.18B |
| Vol | 676.00K | Avg Vol | 1.42M | EPS | -1.67 | P/E | -35.00 | Forward P/E | -26.34 |
| Beta | 0.27 | Short Ratio | 4.54 | Inst. Own | 88.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 48.71 | 200-d Avg | 33.96 | 1yr Est | 72.22 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-11 | 2026-09 | -0.43 | N/A | N/A | N/A |
| 2026-08-05 | 2026-06 | -0.39 | -0.49 | -0.1 | -26.56% |
| 2026-05-07 | 2026-03 | -0.44 | -0.38 | 0.06 | 13.64% |
| 2026-03-03 | 2025-12 | -0.42 | -0.48 | -0.06 | -14.29% |
| 2025-11-12 | 2025-09 | -0.43 | -0.32 | 0.11 | 25.58% |
| 2025-08-13 | 2025-06 | -0.53 | -0.49 | 0.04 | 7.55% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-06 | Stifel | Upgrade | Buy | Buy |
| 2026-08-06 | Guggenheim | Upgrade | Buy | Buy |
| 2026-08-06 | Goldman Sachs | Upgrade | Buy | Buy |
| 2026-07-21 | Goldman Sachs | Upgrade | Buy | Buy |
| 2026-07-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-01 | Stifel | Upgrade | Buy | Buy |
Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-07 | BALLAL RAHUL D. | Director | 22.34K | Sale |
| 2026-07-16 | COLLINS HELEN LOUISE | Officer | 25.00K | Sale |
| 2026-08-03 | DERYNCK MIKA K | Director | 0.00 | Sale |
| 2026-02-16 | HEYMAN RICHARD A | Director | 0.00 | Sale |
| 2026-07-16 | HOHL BENJAMIN | Chief Financial Officer | 46.05K | Sale |
| 2025-11-16 | KINTZ SAMUEL | Chief Executive Officer | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Orbimed Advisors LLC. | 7.96M | 472.96M | 10.86% |
| 2026-03-30 | FMR, LLC | 6.83M | 405.79M | 9.32% |
| 2026-03-30 | Polar Capital Holdings PLC | 5.07M | 301.02M | 6.91% |
| 2026-06-29 | Blackrock Inc. | 4.36M | 259.05M | 5.95% |
| 2026-03-30 | Commodore Capital Lp | 3.28M | 194.60M | 4.47% |
| 2026-03-30 | Vestal Point Capital, LP | 3.25M | 193.11M | 4.44% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.62M | 96.04M | 2.21% |
| 2026-06-29 | Fidelity Select Portfolios-Select Health Care Portfolio | 1.36M | 81.10M | 1.86% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 1.12M | 66.78M | 1.53% |
| 2026-05-30 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.11M | 66.02M | 1.52% |
| 2026-06-29 | Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 747.60K | 44.42M | 1.02% |
| 2026-06-29 | Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 689.92K | 40.99M | 0.94% |